Background The treatment of actinic keratosis (AK) is a potentially effective strategy for the prevention of cutaneous squamous cell carcinoma (cSCC). However, the patient perspective on potential benefits of AK treatment in terms of skin cancer reduction has received little attention to date. Objectives (i) To investigate patient preferences for topical treatments for AK using a discrete-choice experiment (DCE); (ii) to evaluate patient willingness to trade between clinical benefit and medical burden. Methods The DCE was conducted as part of a study to establish the feasibility of a phase III randomized controlled trial evaluating the prevention of cSCC using currently available topical interventions. Preferences were elicited by asking patients to make a series of choices between treatment alternatives with different hypothetical combinations of attribute levels. Willingness to trade between treatment attributes was estimated using a flexible-choice model that allows for the heterogeneity of patient preferences. Results A total of 109 patients with AK completed the DCE. The majority of patients who expressed valid preferences were willing to accept some reduction in both prophylactic and cosmetic efficacy to reduce the burden of the treatment regimen, the severity of skin reaction and other adverse effects. Patients may reject treatment if the perceived therapeutic benefit is outweighed by the subjective burden of treatment. Conclusions Evidence of significant variation in the perceived utility of treatments across patients highlights the importance of taking individual patient preferences into account to improve AK treatment acceptability and adherence.
Summary
Background The treatment of actinic keratosis (AK) is a potentially effective strategy for the prevention of cutaneous squamous cell carcinoma (cSCC). However, the patient perspective on potential benefits of AK treatment in terms of skin cancer reduction has received little attention to date. Objectives (i) To investigate patient preferences for topical treatments for AK using a discrete-choice experiment (DCE); (ii) to evaluate patient willingness to trade between clinical benefit and medical burden. Methods The DCE was conducted as part of a study to establish the feasibility of a phase III randomized controlled trial evaluating the prevention of cSCC using currently available topical interventions. Preferences were elicited by asking patients to make a series of choices between treatment alternatives with different hypothetical combinations of attribute levels. Willingness to trade between treatment attributes was estimated using a flexible-choice model that allows for the heterogeneity of patient preferences. Results A total of 109 patients with AK completed the DCE. The majority of patients who expressed valid preferences were willing to accept some reduction in both prophylactic and cosmetic efficacy to reduce the burden of the treatment regimen, the severity of skin reaction and other adverse effects. Patients may reject treatment if the perceived therapeutic benefit is outweighed by the subjective burden of treatment. Conclusions Evidence of significant variation in the perceived utility of treatments across patients highlights the importance of taking individual patient preferences into account to improve AK treatment acceptability and adherence.
What's already known about this topic?
• There are multiple therapies of varying efficacy licensed for the treatment of actinic keratosis (AK), but none yet proven to reduce skin cancer incidence.
• The treatment of AK is a potential strategy for skin cancer prevention, but is feasible only if patients are willing to consent and adhere to therapy.
• All AK treatments carry a therapeutic burden including pain, local skin inflammation and inconvenience of regimen.
• Discrete-choice experiments (DCE) are used increasingly to elicit patient preferences and thereby improve adherence to treatment.
What does this study add?
• This is the first study to investigate patient willingness to undergo AK treatment using a DCE.
• The majority of patients are able to discriminate between treatment characteristics and many of these patients are willing to make trade-offs between attributes.
• Patients are prepared to accept some reduction in efficacy in order to reduce treatment burden.
• Knowledge of patient preferences will help to optimize the design of treatment protocols given that no currently available treatment for AK is clearly superior in terms of both greater clinical benefit and reduced medical burden.
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer in the U.K., accounting for approximately 23% of the 132 000 new cases of nonmelanoma skin cancer registered in 2014.
1,2 The incidence of cSCC has more than doubled in the past 10 years and rates are predicted to continue rising with the increasing population of elderly individuals, placing a significant burden on healthcare resources.
3
Ultraviolet radiation is the principal environmental carcinogen and an estimated 23% of the U.K. population over 60 years of age have significant sun damage and precancerous skin lesions in the form of actinic keratosis (AK). 4 AK lesions are considered to be precursor lesions for cSCC with a number of studies demonstrating a close relationship between number of AK lesions and cSCC risk, [5] [6] [7] with 65% of cSCCs arising from previously identified AKs. 8 Treatment of AK might therefore provide an effective strategy for cSCC prevention, although this hypothesis has yet to be subjected to rigorous testing. 9, 10 AKs can be treated individually with lesion-directed therapies such as surgery or cryotherapy, or a whole area of skin bearing multiple AKs can be treated with field-directed therapy, which also aims to clear subclinical AK. A number of topical AK treatments with differing mechanisms of action are currently licensed in the U.K. for self-administration [e.g. diclofenac gel; 5-fluorouracil (5-FU) cream; imiquimod cream; ingenol mebutate gel]. They vary in terms of therapeutic burden to patients (e.g. frequency of application, duration of treatment course, severity of local skin reactions and adverse effects), as well as their efficacy (i.e. proportion of AKs cleared and persistence of clearance). For example, topical diclofenac 3% gel tends to cause fewer local skin reactions than 5-FU with salicylic acid, but treatment duration is longer and it is less effective in clearing AK. 9 Such factors may impact on patient treatment preferences; understanding such preferences is important for improving acceptability of, and adherence to, these topical AK treatments.
11
This study investigated patient preferences for topical AK treatments by means of a discrete-choice experiment (DCE). DCEs are used increasingly in healthcare research to elicit patient preferences. 12 They are based on the premise that medical treatments are characterized by a set of attributes and that the attractiveness of a specific treatment is a function of the levels of these attributes. 13 The relative importance of attributes is assessed by offering patients a series of choices between treatment alternatives that have different hypothetical combinations of attribute levels. This methodology has not previously been applied to understanding patient preferences in the treatment of AK.
Methods

Study design
Patients were presented with a series of choices between two hypothetical topical treatments for AK (A and B) and a 'no treatment' opt-out option in each choice set. The hypothetical nature of the treatments provided an opportunity to examine preferences across a wider range of attribute level combinations than exists in currently available treatments. Moreover, the true attribute levels of existing treatments do not need to be known to elicit patient willingness to trade between attributes. This willingness to trade was estimated using a flexiblechoice model that allows for the heterogeneity of respondents' preferences. The selection of treatment attributes and levels is fundamental to obtaining valid DCE results. 13 In this study, an initial selection was made by one of the authors (C.M.P.) based on a review of the literature and expert knowledge from clinical practice. This initial selection was used in a pilot DCE administered to seven patients with AK who subsequently participated in a focus group exploring their perspectives on the preliminary DCE design. The findings from this exercise were used to modify the initial choice of both attributes and associated levels. Table 1 provides details of the final DCE design. Of the five attributes, three were associated with the burden of medication (intensity and length of treatment, severity of local skin reaction and occurrence of flu-like systemic side-effects) and two with the efficacy of treatment (improvement in skin appearance and reduction in skin cancer risk). Attribute levels were chosen to be comparable, although not identical, with those of currently prescribed creams to ensure the clinical relevance of the results, with three levels specified for the reduction in skin cancer risk and two levels for the four other attributes.
Experimental design techniques 14, 15 were used to construct an orthogonal main-effects plan consisting of 12 of the 48 possible combinations of treatment attributes and levels. To validate patient responses, a further two choice sets were added to the DCE: the first checked for rationality of patient choices by including a treatment with unambiguously higher levels of medical burden and lower levels of clinical efficacy; the second checked for consistency by including a treatment that was identical to one of the main choice sets, but with treatments A and B switched. The sequencing of the 14 choice sets was randomly generated for each individual patient questionnaire to mitigate against bias caused by learning or fatigue. 16 
Study sample and elicitation mode
The DCE was conducted as part of Skin cancer Prevention in Organ Transplant patients (SPOT), a multicentre, randomized, three-arm, open-label, phase II feasibility study comparing topical treatment of AK as a strategy for the prevention of invasive cSCC. 17 Patients were recruited between December 2014 and June 2016, with organ transplant recipients (OTRs) recruited at Manchester Royal Infirmary, the Royal Free Hospital London and Barts Health NHS Trust London, and immunocompetent patients (ICPs) at Churchill Hospital Oxford and Ninewells Hospital Dundee. Inclusion criteria were age 18 years of age and above; at least 10 AKs occurring within the same or on adjacent body sites in immunosuppressed OTRs; and a past or current history of AK in ICPs. The sample size N was determined by a power calculation for the main SPOT study, not the DCE, but the following rule of thumb 18, 19 was used to check that this would be adequate to detect the main effects in the choice-model analysis:
where c = 3 is the largest number of levels specified for any of the attributes (20%, 50% and 60% skin cancer risk reductions); t = 12, the number of choice sets or tasks utilized in the choice-model analysis; and a = 3, the number of alternatives in each task (A, B or no treatment). The DCE formed part of a written questionnaire completed in clinic by patients before starting their randomized intervention (Supplementary Material S1; see Supporting Information). Information collected included demographic data, history of skin problems including AK and previous treatments for AK. A detailed explanation of the DCE was provided to patients, with a trial clinician in attendance to answer queries. Patients were asked to report on their experience of completing the DCE.
Statistical analysis
Preference parameters were estimated based on a random utility model in which the utility or value that patient i assigns to treatment j in choice set s, U ijs , is assumed to be the sum of a systematic component based on the attributes included in the DCE, and an error term e ijs :
where the treatment constant b 0i reflects the relative value of a treatment with maximum burden and minimum efficacy to no treatment at all, the utility weights b ik (k = 1, . . .K) indicate the importance of the attributes A k relative to one another, and the absence of interaction terms between attributes is dictated by the DCE design. The preferred generalized multinomial logit (G-MNL) specification 20 takes preference heterogeneity into account by allowing both the treatment constant and the scale of the error term to vary randomly across patients. The model was estimated in Stata 14 21 by maximum simulated likelihood using 2000 Halton draws. Estimated utility weights were used to calculate patients' willingness to trade between treatment attributes on the assumption that the weights for both reductions in skin cancer risk and improvements in skin appearance are linear over the range of levels specified in the DCE.
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Results
Sample characteristics
Of the 111 patients recruited into the SPOT study, 109 completed the DCE, of whom 48 were OTRs and 61 were ICPs. Patient characteristics are summarized in Table 2 . Patients were predominantly male with mean age 68 (range 46-91) years. Most patients considered their AK to be moderately serious in nature, with over 70% selecting one of the three middle categories equating to moderately serious on a seven-point Likert scale. More than 80% of participants had received prior treatments for AK with more than half reporting previous use of a topical treatment, including 5-FU cream (48%), imiquimod cream (17%) and diclofenac gel (12%). As detailed in Table 2 , there are a few significant differences between the OTR and ICP subpopulations, which include younger age of OTR and acral site of AK. Figure 1 details the selection of the choice-model sample by patient type. Twenty-five respondents failed either one or both of the validity tests and were excluded from the subsequent DCE analysis. Patients were asked how difficult they found the DCE on a five-point Likert scale (Table S1 ; see Supporting Information), with a Mann-Whitney U-test revealing that these patients found the DCE significantly more difficult to complete than those providing valid responses (P < 0Á05). A further 26 patients were classified as 'nontraders': they chose the option with the better level of one specific attribute (most commonly the hypothetical treatment with the higher level of cancer risk reduction; Table S2 ; see Supporting Information) in all choice sets, revealing no willingness to trade between attributes at the levels specified in the study. The choices of these 26 patients are consistent with so-called 'lexicographic preferences' but not with the DCE methodology and therefore they were also excluded. The final choice-model sample comprised the 58 respondents with valid responses whose bestoption choices revealed that they were willing to trade between attributes. In the majority of cases (n = 55) these respondents provided responses for all choice sets. The choice-model estimates are presented in Table 3 . The signs of the estimated utility weights on all treatment attributes are consistent with a priori expectations, as positive values imply preferences for a lower medical burden and higher clinical efficacy. It follows that setting all attribute levels to zero will result in the worst possible hypothetical treatment option, one which has to be applied twice daily for 12 weeks, causes severe inflammation and systemic symptoms and results in only a moderate improvement in skin appearance and a 20% fall in the chance of developing skin cancer. The treatment constant provides a prediction of the mean expected utility value of this treatment option, with the positive value providing strong evidence (P < 0Á01) that it would be preferable to no treatment at all for the typical patient. Nevertheless, the estimate of the SD of the treatment constant indicates significant preference heterogeneity, such that the expected utility value of the worst possible option will be negative -i.e. worse than no treatment at all -for about 0Á3% of patients. The 'no treatment' option was chosen as the best option in six choice sets by one patient in the choice-model sample. A Wald test failed to reject the linearity of utility weights over the range of skin cancer risk reductions included in the DCE (P > 0Á10), with the value of a change from a 20% to a 60% fall being insignificantly different from one-third more than that of a change from a 20% to a 50% fall, holding all other attributes constant.
Patient preferences for treatment attributes
Trade-offs Table 4 shows patients' willingness to trade between treatment attributes based on the estimated utility weights [given the linearity assumption, the implied utility weights for a 1% reduction in skin cancer risk and 1% improvement in skin appearance are, respectively, 0Á056 = (1Á756/30 + 2Á142/ 40)/2 and 0Á020 = 1Á016/50]. With respect to medical burden, patients place the highest value on a reduction in severity of the local skin reaction (from severe to mild), followed by the length and intensity of the treatment regimen (from twice daily for 12 weeks to daily for 1 week) and finally the elimination of flu-like systemic symptoms. Patients are willing to accept increases in the risk of developing skin cancer of 13Á4, 9Á7 and 6Á7 percentage points, respectively -or forego improvements in skin appearance of 37Á0, 26Á9 and 18Á5 percentage points -in order to mitigate these three aspects of treatment burden. Patients value changes in skin cancer risk more highly than in cosmetic outcome, being prepared to accept a 0Á36 percentage-point increase in the risk of developing skin cancer to obtain a one percentage-point improvement in skin appearance.
Discussion
Keratinocyte skin cancers are increasingly common, creating both health burden and expense in our ageing population. They are especially burdensome in immunosuppressed patients, such as OTRs, who have an approximately 100-fold increased risk of developing cSCC and accelerated progression from AK to cSCC. 22 Prevention of cSCC through systematic targeting of the common and visible precursor, AK, sounds logical, but is feasible only if effective treatments are acceptable to the patient population needing to use them. Previous studies of topical AK treatments have included patient-reported outcomes as secondary outcomes, including patients' tolerance of the regimen, satisfaction with the cosmetic appearance and choice of future treatment. However, this is the first study to systematically explore patient preferences for AK treatments using a DCE designed to investigate their willingness to undergo treatment and, if so, to trade between different treatment attributes. Understanding these preferences will help health professionals and decision makers to optimize the design of treatment protocols for AK. This is a live issue because there is no currently available treatment that is clearly superior with respect to acceptability, efficacy and subsequent reduction in skin cancer risk. For example, Stockfleth et al. found that 5-FU cream is more clinically effective than diclofenac gel, but it is less well tolerated with a higher proportion of patients reporting local adverse reactions. In this DCE study, we have shown that the majority of patients are able to discriminate between treatment attributes showing CI, confidence interval. Number of observations 2076 (58 respondents 9 12 choices 9 3 alternatives, minus 12 missing values). Log-likelihood = À346Á1. Akaike information criterion = 710Á2. Bayesian information criterion 761Á0. **P < 0Á05, ***P < 0Á01. Estimates presented as mean (95% confidence interval). A positive willingness to trade means that patients are willing to trade a reduction in medical efficacy for the specified level or improvement in the attribute. *P < 0Á05, **P < 0Á01.
specific preferences that can be incorporated into future strategies to improve adherence. Our results are consistent with a priori expectations in that patients overwhelmingly express preferences for lower treatment burden and higher clinical efficacy. Our results also show that nearly 70% of patients who expressed valid preferences revealed a willingness to make trade-offs between attributes in their treatment option choices. The remainder based their best-option choices on the better level of one specific attribute only and for roughly half of these patients, in both the OTR and ICP subsamples, this single factor was a greater reduction in skin cancer risk. The apparent strength of preferences among this subset of nontraders, even if they are the result of heuristic decision making, 23 may be taken as an indication that they would be almost certain to accept treatment irrespective of the severity of the treatment burden. The choice-model estimates imply that patients who are willing to trade between attributes would accept some reduction in both the prophylactic and cosmetic benefit of treatment in order to reduce the length and intensity of treatment regimens, pain and skin inflammation due to local adverse reactions, and the incidence of other side-effects. Patients' preferences may be influenced by length of treatment course, as in preference for photodynamic therapy, 10 and/or by local (and systemic) adverse events with skin inflammation being a frequent complication of topical treatments for AK. 24 In this DCE study, the hypothetical attribute levels were chosen to provide health professionals with relevant information to make clinical decisions that reflect patient preferences between currently licensed topical treatments. The choice-model estimates also demonstrate significant variation in the value that individual patients place on treatment options, although even the worst possible hypothetical treatment (high medical burden with low clinical efficacy) was preferable to no treatment for virtually all patients. Nevertheless, a very small proportion of patients might be expected to reject such an option, with one participant choosing no treatment as the best option in a number of the choice sets presented in the DCE. Serra-Guillen et al. 25 report that only 70% of patients treated with imiquimod would be willing to repeat the treatment. Moreover, patients who are prepared to accept treatment but do not value it highly might be less likely to adhere to the regimen. The clinical importance of nonadherence has been highlighted in the most recent Cochrane review on AK treatment. 24 Our study has several potential limitations. Firstly, although the design of the DCE was based on expert opinion and further refined by the results of a pilot exercise, it is possible that we did not include all attributes that are relevant to patient preferences for AK treatment. Secondly, respondents may have been unfamiliar with different AK treatments or did not fully understand the nature of the choices that they were being asked to make. However, most respondents had previously received AK treatments -and over half had experienced a topical treatment -with hypothetical attribute levels chosen to be comparable with those of the currently prescribed agents.
Moreover, the DCE was completed in clinic with a research nurse in attendance to check on the respondent's understanding. Thirdly, the DCE design allowed only for main effects and therefore we were unable to identify any specific effects associated with particular combinations of attribute levels. Previous research has found that main effects typically account for the bulk of the variation in a DCE with interactions playing a smaller role. 26 Fourthly, the sample size was determined by a power calculation for the main SPOT study, not the DCE, but an established rule of thumb indicated that the choicemodel sample was more than adequate to detect the main effects. 18, 19 Fifthly, the results may be sensitive to the choicemodel specification. However, a robustness analysis produced virtually identical findings across a range of alternative logit model specifications (Table S3 ; see Supporting Information). Finally, our findings are based on a sample of patients recruited from specialist clinics in a single country (U.K.) and may not necessarily be generalizable to treatment of AK in other settings. Preferences for attributes/levels may differ according to a number of factors including age, sex, education, patient type and prior medical history including previous AK treatments, but we were not able to reliably demonstrate evidence of significant differences in treatment valuations between patients with different observable characteristics given the limited sample size. However, overall, we believe that the clinical setting and patient characteristics are representative of current AK treatment practice in secondary care in the U.K. This study has demonstrated that patients may reject an AK treatment if the perceived value of the therapeutic benefits is outweighed by the subjective costs associated with the medical burden. Moreover, most patients would be prepared to accept some reduction in both the prophylactic and therapeutic efficacy of treatment in order to reduce the length and intensity of the regimen, and local or systemic symptoms including skin inflammation and pain. This will impact the feasibility of skin cancer prevention strategies that include AK treatments. Evidence of significant variation in the perceived utility of treatments between patients highlights the importance of taking individual patient preferences into consideration as part of clinical decision making in order to improve adherence to topical AK treatments.
